Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.28 and has seen 1.97 million shares traded in the recent trading session. The company, currently valued at $576.02M, closed the recent trade at $3.08 per share which meant it gained $0.4 on the day or 14.93% during that session. The TSHA stock price is -26.3% off its 52-week high price of $3.89 and 83.77% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.93 million shares traded. The 3-month trading volume is 2.68 million shares.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting 14.93% in the green today, the stock has traded in the green over the last five days, when the TSHA stock price touched $3.08 or saw a rise of 6.67%. Year-to-date, Taysha Gene Therapies Inc shares have moved 74.01%, while the 5-day performance has seen it change 13.65%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed 22.22%. Short interest in the company has seen 15.81 million shares shorted with days to cover at 4.8.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Figures show that Taysha Gene Therapies Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 14.50% over the past 6 months, with this year growth rate of 60.42%, compared to 21.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 60.70% and 71.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -45.00%.
7 analysts offering their estimates for the company have set an average revenue estimate of $2.13 million for the current quarter. 7 have an estimated revenue figure of $2.13 million for the next quarter concluding in Jun 2024. Year-ago sales stood $4.71 million and $2.4 million respectively for this quarter and the next, and analysts expect sales will shrink by -54.70% for the current quarter and -11.10% for the next.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report between May 09 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders own 24.77% of the company shares, while shares held by institutions stand at 69.75% with a share float percentage of 92.71%. Investors are also buoyed by the number of investors in a company, with Taysha Gene Therapies Inc having a total of 106 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc with over 1.59 million shares worth more than $1.05 million. As of Jun 29, 2023, Vanguard Group Inc held 0.85% of shares outstanding.
The other major institutional holder is Tybourne Capital Management (HK) Limited, with the holding of over 1.5 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $0.99 million and represent 0.80% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. As of Jun 29, 2023, the former fund manager holds about 0.62% shares in the company for having 1.16 million shares of worth $0.77 million while later fund manager owns 0.81 million shares of worth $2.6 million as of Aug 30, 2023, which makes it owner of about 0.43% of company’s outstanding stock.
